Dr. Gray’s research focuses on understanding the social, ethical and medical outcomes related to the use of genomic technologies in cancer care. Her previous and ongoing work focuses on direct-to-consumer genetic testing, physician decision-making in areas of uncertainty, and cancer patient information seeking. Her work aims to understand the relationships between information dissemination, on an individual and population level, and the appropriate and inappropriate adoption of personalized cancer technologies. By studying the way in which information exposure relates to the uptake of genomic technologies and targeted therapies, Dr. Gray aims to understand if and how knowledge and uncertainty contribute to variations in cancer care. Dr. Gray leads a project that aims to establish a robust framework for the generation, interpretation, and clinical implementation of cancer whole-exome sequencing (WES). She and her colleagues are exploring the impact of the integration of somatic and germline WES on patients, oncologists, and institutional policies and practices. Through this work Dr. Gray examines the myriad ethical and social issues provoked by sequencing in cancer care in order to inform the design of systems that harness these emerging technologies and integrate them into high quality high impact cancer care.